Form 4: C4 Therapeutics Executive Paige Mahaney Reports Acquisition of Stock Options and Restricted Stock Units

Paige Mahaney, Chief Scientific Officer of C4 Therapeutics, reports the acquisition of stock options and restricted stock units in the company.

Summary

• Paige Mahaney, Chief Scientific Officer of C4 Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
• On October 28, 2024, Mahaney acquired 76,800 shares of common stock in the form of restricted stock units (RSUs) at a price of $0.
• These RSUs vest in four equal annual installments starting October 28, 2025, contingent upon continued service.
• Mahaney also acquired options to purchase 345,600 shares of common stock at an exercise price of $6.
• 25% of these options vest on October 28, 2025, with the remaining portion vesting in 36 equal monthly installments, also contingent upon continued service.
• Following these transactions, Mahaney directly owns 76,800 shares of common stock and options for 345,600 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. It reflects standard executive compensation practices, incentivizing long-term commitment. There are no immediate negative implications.

Positives

• The acquisition of RSUs and stock options by a key executive like the Chief Scientific Officer can be seen as a positive sign, aligning their interests with the company's long-term success.
• The vesting schedules for both the RSUs and stock options incentivize continued service and commitment from the executive.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedules suggest an expectation of continued service from the executive.

Industry Context

Form 4 filings are a standard part of regulatory compliance for publicly traded companies, providing transparency into the transactions of company insiders. This filing indicates standard compensation practices for executives in the biotechnology industry, often including stock options and RSUs to align interests with shareholders.

Comparison to Industry Standards

• Stock option grants and RSU awards are common compensation components for executives in biotech companies like C4 Therapeutics.
• Comparable companies such as Arvinas, Inc. and Kymera Therapeutics also utilize similar equity-based compensation structures to incentivize key personnel.
• The vesting schedules described are fairly standard, aligning with typical industry practices for retaining talent and driving long-term performance.

Stakeholder Impact

• The granting of stock options and RSUs aligns the executive's interests with those of the shareholders, potentially driving long-term value creation.
• Employees may view this as a positive sign, indicating the company's commitment to its leadership team.

Key Dates